Dermata Therapeutics(DRMAW)

Focus: Dermata Therapeutics is a public dermatology-focused biotech company founded in 2004, headquartered in San Diego, with a pipeline of topical treatments for acne, rosacea, and atopic dermatitis. The company is pre-revenue and operating at a modest R&D scale.

Dermatology

Profile data last refreshed 19h ago · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

About Dermata Therapeutics

AI assessmentNot Hiring

No open roles listed right now. Follow Dermata Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

2/9 — Limited

Company HealthSolid

Pipeline

Mid-stage

1 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

DMT210 Topical Gel

Atopic Dermatitis

Phase 2

Clinical Trials (1)

NCT02949960DMT210 Topical Gel in the Treatment of Atopic Dermatitis

Phase 2

Help build intelligence for Dermata Therapeutics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Access to a focused, single-disease-area platform in high-prevalence dermatology indications (acne, rosacea, atopic dermatitis) with multiple shots on goal via DMT210 and DMT310 programs
Early-stage biotech opportunity where individual contributors can have outsized impact on drug development decisions and regulatory strategy
Publicly traded status provides liquidity and potential upside if Phase 2/3 programs advance, though at higher risk than later-stage peers

Watch Out For

Critical cash constraint: only $3M cash in FY2025 against $8M R&D spend and $12.3M net loss, creating severe runway risk and potential dilution or restructuring within 12–18 months
No active job openings and minimal headcount data suggest the company is operating lean with limited hiring pipeline or career mobility
Pre-revenue status with only Phase 2/3 assets and no approved products means zero commercial infrastructure, clinical validation still pending, and high clinical failure risk typical of early-stage biotech

Generated by Claude from Dermata Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

DMT310

Acne Vulgaris

Phase 2

Clinical Trials (1)

NCT04106778DMT310-003 Topical in the Treatment of Acne Vulgaris

Phase 2

DMT310

Acne Vulgaris

Phase 2

Clinical Trials (1)

NCT03536637DMT310-001 Topical in the Treatment of Acne Vulgaris

Phase 2